RFK Jr. says U.S. won’t threaten pharmaceutical patents to push for lower drug prices
The use of march-in rights to target pricy drugs has been a controversial issue across several administrations.
Related Articles
OpenAI will offer its tech to US national labs for nuclear weapons research | TechCrunch
OpenAI says it plans to let U.S. National Laboratories use its AI models for nuclear weapons security and other scientific projects.
The top deals to know this week
Check out who’s buying and selling in this week’s roundup of healthcare mergers, acquisitions and joint ventures.
From the Futurology community on Reddit: Geothermal power may be about to kill the Nuclear Energy industry. Drilling costs are falling so fast, by 2027 it will be able to provide baseload electricity at the same price – but unlike nuclear power, it can be built quickly and on budget.
Explore this post and more from the Futurology community
When and How To Sleep Train Your Baby
You can’t take the sleepless nights anymore, and you’re thinking it might be time to sleep train your baby. But are they old enough? What…
Effects of cold-water immersion on health and wellbeing: A systematic review and meta-analysis
Background Cold-water immersion (CWI) has gained popularity as a health and wellbeing intervention among the general population. Objective This systematic review and meta-analysis aimed to…
Suzetrigine: First-in-Class Nonopioid Pain Therapy Is Approved by FDA
Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as a selective…
Study Identifies Gender Differences in Early PTSD Symptoms
Women experience more severe early PTSD symptoms than men, with re-experiencing and avoidance clusters being strongest. Men showed stronger anxious arousal patterns.
“People Will Die”: The Trump Administration Said It Lifted Its Ban on Lifesaving Humanitarian Aid. That’s Not True.
Organizations that provide vital care for desperate and vulnerable people around the world have been forced to halt operations, turn away patients and lay off…
$2.2 Million per Bitcoin in Play, Max Keiser Says, As Saylor Gets Featured by Forbes
Vocal Bitcoin expert Max Keiser shares bullish reaction to Saylor’s appearance in Forbes
